2023 was a tough yr with the biopharma sector, with several organizations downsizing and restructuring their workforces to stay afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and existence sciences sector from the latter Element of 2023 and possess ongoing their upswing into https://sites.google.com/view/bio-sites/blog